Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: Application to a pharmacokinetic study

Postbiotics: Functional Food Materials and Therapeutic Agents for Cancer, Diabetes, and Inflammatory Diseases

Postbiotics are (i) "soluble factors secreted by live bacteria, or released after bacterial lysis, such as enzymes, peptides, teichoic acids, peptidoglycan-derived muropeptides, polysaccharides, cell-surface proteins and organic acids"; (ii) "non-viable metabolites produced by microorganisms that exert biological effects on the hosts"; and (iii) "compounds produced by microorganisms, released from food components or microbial constituents, including non-viable cells that, when administered in adequate amounts, promote health and wellbeing". A probiotic- and prebiotic-rich diet ensures an adequate supply of these vital nutrients. During the anaerobic fermentation of organic nutrients, such as prebiotics, postbiotics act as a benevolent bioactive molecule matrix. Postbiotics can be used as functional components in the food industry by offering a number of advantages, such as being added to foods that are harmful to probiotic survival. Postbiotic supplements have grown in popularity in the food, cosmetic, and healthcare industries because of their numerous health advantages. Their classification depends on various factors, including the type of microorganism, structural composition, and physiological functions. This review offers a succinct introduction to postbiotics while discussing their salient features and classification, production, purification, characterization, biological functions, and applications in the food industry. Furthermore, their therapeutic mechanisms as antibacterial, antiviral, antioxidant, anticancer, anti-diabetic, and anti-inflammatory agents are elucidated.

Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies

Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension. The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Patients often will exhibit overlapping characteristics from more than one of these mechanisms. The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism. Stockings, abdominal binders, and vasoconstrictors are used to enhance venous return in partial neuropathic POTS. Exercise and volume expansion are the main treatment strategies for hypo-volemic POTS. For hyperadrenergic POTS, beta-blockers and avoidance of norepinephrine reuptake inhibitors is important. Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.

The effect of ultrasonic irradiation on the morphology of NiO/Co3O4 nanocomposite and its application to the simultaneous electrochemical determination of droxidopa and carbidopa

The present work deals with the preparation of NiO/Co₃O₄ nanocomposites in presence of ultrasonic irradiation, and its use in electrochemical determination of Parkinson's drugs. NiO/Co₃O₄ nanocomposites are prepared using ultrasound assisted method. The impact of ultrasonic irradiation power (0, 75, 150, 300 and 600 W) on the structure and morphology of NiO/Co₃O₄ nanocomposites was investigated. Various particle morphologies were attained because of the existence of ultrasonic irradiation. The nanoparticles' structure exhibited more uniformity whilst the particles sizes and nanoparticle accumulation was reduced when ultrasonic irradiation power was increased. The NiO/Co₃O₄ nanocomposite was determined via X-ray diffraction, scanning electron microscopy i.e. SEM as well as energy dispersion X-ray spectroscopy (EDX). Drop casting NiO/Co₃O₄ nanocomposites suspension on glassy carbon electrode was employed to fabricate the modified glassy carbon electrode (NiO/Co₃O₄/GCE). The electrochemical studies on the NiO/Co₃O₄ nanocomposite towards droxidopa and carbidopa were experimented via cyclic voltammetry (CV), chronoamperometry (CHA) and differential pulse voltammetry (DPV). The CV examinations displayed increased catalytic behavior of droxidopa because of synergistic impact of the nanocomposite that was bolstered through enhanced material surface roughness. By using differential pulse voltammetry, the droxidopa detection limit and linear range was determined as 0.01 μM and 0.1-500.0 μM, respectively. Also, the adjusted electrode was implemented to ascertain droxidopa in the presence of carbidopa by differential pulse voltammetry. This sensor exhibited long term reproducibility and stability. Droxidopa and carbidopa quantification within biological specimens of fluids i.e. human urine and serum were conducted to validate the suitability in the application of this sensor.

Orthostatic hypotension for the cardiologist

PURPOSE OF REVIEW

Orthostatic hypotension is a phenomenon commonly encountered in a cardiologist's clinical practice that has significant diagnostic and prognostic value for a cardiologist. Given the mounting evidence associating cardiovascular morbidity and mortality with orthostatic hypotension, cardiologists will play an increasing role in treating and managing patients with orthostatic hypotension.

RECENT FINDINGS

The American College of Cardiology, American Heart Association, and Heart Rhythm Society recently published consensus guidelines on the diagnosis, treatment, and management of syncope and their instigators, including orthostatic hypotension. Additionally, consensus guidelines have also been recently updated, reinforcing the universal definition orthostatic hypotension and its closely associated pathologies. Finally, the United States Food and Drug Administration (FDA) recently approved droxidopa, a synthetic oral norepinephrine prodrug, in 2014 for the treatment of neurogenic orthostatic hypotension (nOH), and it represents a well tolerated, effective, and easy to use intervention for nOH. This represents only the second drug approved by the FDA for orthostatic hypotension, the first being midodrine in 1986. A handful of smaller head-to-head studies have pitted not only pharmacologic agents to one another but also nonpharmacologic interventions to pharmacologic agents. Additionally, recent studies have also reported on more convenient screening tools for orthostatic hypotension.

SUMMARY

Though there have been many advances in the management of orthostatic hypotension, nOH remains a chronic, debilitating, and often progressively fatal condition. Cardiologists can play a very important role in optimizing hemodynamics in this patient population to improve quality of life and minimize cardiovascular risk.